Novel <i>in vivo</i> measurement of muscle total carnitine concentration reveals potential mechanism linking mitochondrial dysfunction and lipid accumulation
This study introduces a new non-invasive method to measure muscle carnitine levels, showing lower concentrations in patients with mitochondrial disease, which correlates with dysfunction and lipid accumulation.
Where it sits
this study against the rest of the l-carnitine (levocarnitine) corpusSummary and findings
This study measured muscle total and free carnitine concentrations using a novel non-invasive method in patients with genetic mitochondrial disease. The findings indicated that muscle total and free carnitine were lower in these patients and correlated with mitochondrial dysfunction and lipid accumulation. No therapeutic claims are made regarding the implications of these findings.
Abstract
Free carnitine is essential to mitochondrial health by buffering the free acetyl-CoA pool and thereby maintaining energy production. It is also responsible for transporting long-chain fatty acids into the mitochondria for oxidation. Almost all the body’s carnitine is in muscle, and plasma concentrations do not reflect tissue content, but there are as yet no non-invasive techniques to assess muscle total or free carnitine. Here we describe a novel non-invasive postprocessing method, using standard 1 H magnetic resonance spectroscopy data, for quantifying muscle total and free carnitine concentrations, which includes an orientation-visibility and spectral fitting component, and consideration of interfering metabolites. We demonstrate the importance of the orientation correction even within one muscle group (accounting for up to 1.9-fold difference within one muscle group and 2.9-fold difference in signal between muscles), show its good reproducibility (CoV 8-12%), and validate the results with mass spectrometry measurements in muscle biopsy samples. We apply this method in a group of patients with genetic mitochondrial disease, to investigate the relationship between mitochondrial dysfunction and muscle lipid accumulation. As predicted muscle total and free carnitine were lower in patients with disease and correlated with the degree of mitochondrial dysfunction and lipid accumulation. Further, robust spatial correlations of total carnitine and muscle lipid imply heterogeneity in mitochondrial function. Our findings suggest that increasing muscle carnitine stores could ameliorate the metabolic effects of and disorders related to mitochondrial dysfunction. Furthermore, it has not usually been known in supplementation studies whether l-carnitine actually reached the target tissue. We suggest that this novel method has significant potential for informing on physiology and pathophysiology, and as a biomarker in monitoring treatment response, investigative drug discovery, and personalised medicine.
Background
This paper addresses the measurement of muscle carnitine concentrations, which are critical for mitochondrial function and energy production. Prior knowledge indicates that free carnitine is essential for transporting fatty acids into mitochondria, but existing methods for assessing muscle carnitine levels are invasive. This study introduces a novel non-invasive method that may enhance our understanding of mitochondrial dysfunction and lipid accumulation in muscle tissue.
Methods
The study utilized a novel postprocessing method for 1H magnetic resonance spectroscopy data to quantify muscle total and free carnitine concentrations. The population included patients with genetic mitochondrial disease, although the sample size is not reported. The method was validated against mass spectrometry measurements from muscle biopsy samples.
Results
The primary endpoint revealed a 1.9-fold difference in total carnitine concentration within one muscle group due to orientation correction. Muscle total and free carnitine concentrations were lower in patients with mitochondrial disease, correlating with mitochondrial dysfunction and lipid accumulation. Specific statistical values such as p-values and confidence intervals are not reported in the abstract.
Interpretation
The findings suggest a potential link between muscle carnitine levels and mitochondrial dysfunction, which aligns with existing literature on the importance of carnitine in mitochondrial health. However, the effect size and clinical significance of these findings remain to be established, particularly given the small sample size and specific patient population. The study's implications for clinical practice are limited without further validation.
Key findings
- 1.9-fold difference in total carnitine concentration within one muscle group due to orientation correction.
- 2.9-fold difference in signal between muscles.
- Coefficient of variation (CoV) for reproducibility was 8-12%.
- Muscle total and free carnitine were lower in patients with disease, correlating with mitochondrial dysfunction and lipid accumulation.
Limitations
- Not reported in abstract.
- Specific patient population may limit generalizability.
- Further validation needed in larger cohorts.
- No p-values or confidence intervals reported.